Fosun Pharma stock: Q3 adjusted profit falls despite reported gain
Published on 10/30/2026 at 01:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFosun Pharma earnings show mixed signals
- Third-quarter revenue increased modestly, while reported profit benefited from non-recurring effects.
- Innovative medicines remained a growth area during the first nine months.
- Higher research spending supports the company's longer-term pipeline strategy.
Fosun Pharma reported a mixed third-quarter performance on October 28, 2026, with reported profit rising while earnings excluding one-time items fell 8.3% year over year. City News Service said attributable profit reached about CNY 946 million and revenue increased 1.4% to roughly CNY 10 billion.
Reported profit and core earnings diverged
The difference reflected a higher licensing contribution in the year-earlier period, weaker contributions from associates and joint ventures, and increased foreign-exchange losses. The figures therefore point to a more cautious reading of headline profit growth than the reported increase alone would suggest.
For the first nine months, revenue rose 3.6% to approximately CNY 30.5 billion, while attributable profit increased 5.7% to about CNY 2.67 billion. The company classified innovative-drug revenue as a key growth driver, with that business expanding 15.5% and representing around 35% of pharmaceutical revenue.
Innovation remains the strategic focus
Fosun Pharma's development strategy continues to rely on expanding innovative medicines and strengthening its pipeline. Research and development spending on innovative medicines increased sharply during the first nine months, indicating that management is prioritizing future product growth even as quarterly underlying earnings came under pressure.
Investor context and quote
The licensed Lang & Schwarz dataset showed Fosun Pharma at 1.82 euros on October 29, 2026, at 23:00:23 Berlin time. Investors should distinguish that dated quote from the company's Hong Kong and mainland China trading venues and weigh the earnings mix rather than focusing only on reported profit.
For a directly updated view, see the real-time quote of Fosun Pharma stock.
Fosun Pharma at a glance
- Company: Fosun Pharma
- ISIN: CNE100001M79
- Lang & Schwarz quote: 1.82 euros, October 29, 2026, 23:00:23 Berlin time
- Third-quarter revenue: approximately CNY 10 billion, up 1.4% year over year
- First-nine-month revenue: approximately CNY 30.5 billion, up 3.6% year over year
The current market reports provide the broader market setting without implying a direct link to Fosun Pharma's share performance.
Further company-specific developments are collected in More news and analyses on Fosun Pharma stock.
